SCHEMBL7941730

SCHEMBL7941730

Cc1nc(C)c(C(=O)Nc2cccc(CNc3cccnc3N)c2)s1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 9/20 0.59
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
TP53 P04637 1/20 0.55
RECQL P46063 1/20 0.51
ALDH1A1 P00352 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 2/20 0.44
PKM P14618 1/20 0.44
POLB P06746 2/20 0.44
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44
PARP1 P09874 1/20 0.43
KDR P35968 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7935757 0.86 RAB9A (0.50) BACE1RAB9ANPC1SMN1; SMN2TP53
SCHEMBL7940531 0.84 BACE1 (0.49) BACE1RAB9ANPC1SMN1; SMN2TP53
SCHEMBL7942148 0.82 BACE1 (0.61) BACE1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL7940400 0.82 BACE1 (0.60) BACE1AURKARPS6KB1PARP1KDR
SCHEMBL7945236 0.80 BACE1 (0.54) BACE1
SCHEMBL7942157 0.80 BACE1 (0.60) BACE1AURKARPS6KB1PARP1KDR
SCHEMBL7942031 0.80 BACE1 (0.65) BACE1AURKARPS6KB1KDR
SCHEMBL7933424 0.79 BACE1 (0.73) BACE1SMN1; SMN2ALDH1A1KMT2AAURKA
SCHEMBL7944660 0.79 BACE1 (0.62) BACE1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL7942164 0.79 BACE1 (0.59) BACE1RAB9ANPC1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
EP-2360155-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY Shionogi & Co., Ltd. (JP) 2011-08-24 EP disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885RAB9A 1287/4885NPC1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.